NYSEMKT: PLX
Protalix Biotherapeutics Inc Stock Ownership - Who owns Protalix Biotherapeutics?

Insider buying vs selling

Have Protalix Biotherapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Dror BashanPRESIDENT AND CEO2025-12-1956,000$1.81
$101.36kBuy
Amos BarshalevDirector2025-11-18168$1.87
$314.16Sell
Aharon SchwartzDirector2025-06-10129,000$1.60
$205.88kBuy

1 of 1

PLX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when PLX insiders and whales buy or sell their stock.

PLX Shareholders

What type of owners hold Protalix Biotherapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Biocell Ltd37.85%30,442,586$93.15MInsider
Phillip Md Et Al Frost22.61%18,184,566$55.64MInsider
Zeev Bronfeld20.68%16,628,800$50.88MInsider
Eyal Sheratzki17.99%14,466,319$44.27MInsider
Camber Capital Management LP13.40%10,775,000$32.97MInsider
Marathon Investments Ltd8.15%6,556,381$20.06MInsider
Sharon Toussiacohen8.15%6,556,381$20.06MInsider
Amos Barshalev7.70%6,193,546$18.95MInsider
Technorov Holdings 1993 Ltd7.69%6,186,046$18.93MInsider
Eli Hurvitz6.66%5,353,923$16.38MInsider

1 of 3

PLX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
PLX9.84%90.16%Net BuyingNet Buying
FENC4.33%95.67%Net SellingNet Selling
OABI39.80%23.06%Net BuyingNet Selling
STTK66.41%23.46%Net BuyingNet Selling
PALI90.96%5.57%Net BuyingNet Buying

Protalix Biotherapeutics Stock Ownership FAQ

Who owns Protalix Biotherapeutics?

Protalix Biotherapeutics (NYSEMKT: PLX) is owned by 18.53% institutional shareholders, 169.86% Protalix Biotherapeutics insiders, and 0.00% retail investors. Biocell Ltd is the largest individual Protalix Biotherapeutics shareholder, owning 30.44M shares representing 37.85% of the company. Biocell Ltd's Protalix Biotherapeutics shares are currently valued at $93.15M.

If you're new to stock investing, here's how to buy Protalix Biotherapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.